Riskpilot← Back to searchSign inGet full accessOmniGyn AB
ABActiveOrg 5567970610Rörstrandsgatan 23General medical practice activities · NACE 8621Est. 20091 employees
Revenue 2025
SEK 71K
-41% vs 2024
EBITDA margin
-145.8%
-1446% vs 2024
Equity ratio
89.8%
Financial strength
Net profit 2025
SEK -20K
-157% vs 2024
| Revenue | SEK 71K | -41% |
| EBITDA | SEK -104K | -1446% |
| Net profit | SEK -20K | -157% |
| Total assets | SEK 402K | -15% |
| Equity | SEK 361K | -5% |
| Employees | 1 | — |
Legal name
OmniGyn AB
Org number
5567970610
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
14 december 2009
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget bedriver medicinsk hälso- och sjukvård, samt därmed förenlig verksamhet. Bolaget bedriver även hälsoarbete, utbildning och informationsarbete.Funktionsmedicinska utredningar och behandlingar ingår i verksamheten. Inom ramen för bolaget kan även inrymmas engagemang i life-science företag. Viss försäljning kan förekomma av varor inom ovanstående område. Medicinsk akupunktur kan komma att erbjudas. Bolaget bedriver också tillverkning och försäljning av hantverksprodukter.
Address
Rörstrandsgatan 23
Email
cilla@omnigyn.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 428 | 710 | 346 | 335 | 395 | 221 | 121 | 71 |
| Staff expenses | — | — | — | — | — | — | — | −115 | −59 | −28 | −27 |
| EBITDA | −76 | −14 | −82 | 211 | 305 | 71 | −105 | 39 | −24 | −7 | −104 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — | — | — |
| EBIT | −76 | −14 | −82 | 211 | 305 | 71 | −105 | 39 | −24 | −7 | −104 |
| Net financials | — | — | — | — | — | — | — | 0 | 8 | 8 | 3 |
| Profit before tax | −8 | 31 | −73 | 176 | 225 | 71 | −105 | 39 | −17 | 36 | −20 |
| Tax | −0 | −7 | −2 | −26 | −53 | −19 | −0 | — | — | — | — |
| Net profit | −8 | 24 | −75 | 150 | 172 | 52 | −105 | 39 | −17 | 36 | −20 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 288 | 506 | 169 | 317 | 669 | 825 | 775 | 644 | 516 | 472 | 402 |
| Equity | 106 | 129 | 55 | 205 | 376 | 428 | 323 | 362 | 345 | 382 | 361 |
| Long-term debt | 110 | 145 | 105 | 0 | 0 | 0 | 281 | 162 | 42 | 0 | — |
| Short-term debt | 17 | 222 | 9 | 77 | 178 | 282 | 55 | 5 | 13 | 10 | 41 |
| Total debt | 127 | 367 | 114 | 77 | 178 | 282 | 336 | 167 | 55 | 10 | 41 |
EBITDA margin
-145.8%
This company
15.8%
Market median
-1023% vs market
20152025
Equity ratio
89.8%
This company
38.2%
Market median
+135% vs market
20152025
Return on equity
-5.7%
This company
18.4%
Market median
-131% vs market
20152025
Net profit margin
-28.8%
This company
8.1%
Market median
-456% vs market
20152025
Asset turnover
0.18×
This company
1.12×
Market median
-84% vs market
20152025
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20152025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EC | Audit | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of OmniGyn AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eva Christina Strokirk | Audit | 0 companies |
| Anna Teresa Beckvid Tolstoy | Deputy Board Member | 0 companies |
| Cecilia Wernekinck | Board of Directors | 0 companies |
| Anna Gabriella Salamon | Deputy Board Member | 0 companies |